Nuvilex, Inc. (OTCQB: NVLX) announced today it has entered into discussions to acquire the next generation live cell encapsulation technology that serves as the platform for multiple cancer therapies.
While the recently acquired pancreatic cancer therapy is a single-use derivative of the live cell encapsulation technology, the acquisition of the underlying platform would enable Nuvilex to pursue a substantial variety of other cancer applications.
Cell encapsulation allows placement of any cell type into the body after enclosing the cells inside tiny beads. Depending on the cell type placed into the beads, or encapsulated, these cells enable continuous and/or controlled production and release of therapeutic molecules. This includes activated drugs, as is the case with the pancreatic cancer treatment technology already owned by Nuvilex.
The beads are made of a naturally occurring, nontoxic, biocompatible material that protects the encapsulated cells from attack by the body's defence mechanisms. At the same time, the beads provide a microenvironment that enables encapsulated cells to survive for long periods of time.
Dr. Robert F. Ryan, Corporate Executive of Nuvilex commented, "We consider the benefits of using the cell encapsulation technology for pancreatic cancer treatment to be extensive. Through the use of this technology, we believe we will be able to extend the lifespan of patients with advanced pancreatic cancer as well as giving them a better quality of life while they endure their disease. We also feel cell encapsulation may prove useful in the treatment of cancers other than pancreatic and are interested in this potential extension of what we have already acquired from SG Austria."
NCCN global meeting focuses on cancer care in the MENA region